Second–line chemotherapy for non—small–cell lung cancer Frank V. Fossella OriginalPaper Pages: 96 - 101
Management of elderly patients with lung cancer Malcolm R. RansonShane WhiteNicholas Thatcher OriginalPaper Pages: 90 - 95
The role of new agents in advanced non—small–cell lung carcinoma Corey J. Langer OriginalPaper Pages: 76 - 89
Hyperfractionated radiotherapy for lung cancer Eric L. GressenWalter J. Curran Jr OriginalPaper Pages: 71 - 75
Induction chemotherapy or chemoradiotherapy before surgery for non-small-cell lung cancer Kathy S. Albain OriginalPaper Pages: 54 - 63
Postoperative radiotherapy in resected non-small-cell lung cancer: Every creek has two banks David H. JohnsonAndrew Turrisi Clinical Trials Review Pages: 51 - 53
Melanoma peptide vaccines: From preclinical background to clinical trials Jeffrey Weber OriginalPaper Pages: 38 - 47
Novel oral chemotherapy agents Melanie E RoycePaulo M. HoffRichard Pazdur OriginalPaper Pages: 31 - 37
Antisense cancer therapy: The state of the science David M. KushnerRobert H. Silverman OriginalPaper Pages: 23 - 30
Angiogenesis inhibitors Thelma R. TennantCarrie W. Rinker-SchaefferWalter M. Stadler OriginalPaper Pages: 11 - 16
Cancer, psychologic factors, and behavior: A complex and controversial relationship Maurie Markman Editor’s Commentary Pages: 2 - 3
Cyclooxygenase-2 as a target for prevention of colorectal cancer Monica M. Bertagnolli OriginalPaper Pages: 173 - 178
The role of carcinoembryonic antigen monitoring in management of colorectal cancer Mary F. MulcahyAl B. Benson III OriginalPaper Pages: 168 - 172
Novel chemotherapy agents for colorectal cancer: Oral fluoropyrimidines, oxaliplatin, and raltitrexed Melanie E. RoycePaulo M. HoffRichard Padzur OriginalPaper Pages: 161 - 167
Combined modality therapy for esophageal cancer Ziv GamlielMark J. Krasna OriginalPaper Pages: 149 - 154
Clinical implications of biomarkers in head and neck cancer Wayne M. Koch OriginalPaper Pages: 129 - 137
Quality-of-life issues in head and neck cancer Ehab HannaAllen C. Sherman OriginalPaper Pages: 124 - 128
Altered fractionation in the treatment of head and neck cancer Kenneth S. HuLouis B. Harrison OriginalPaper Pages: 110 - 123
Integration of chemotherapy into the definitive management of squamous cell head and neck cancer David J. Adelstein Clinical Trials Review Pages: 97 - 98
Do we need a new strategy to treat metastatic breast cancer? Joseph R. BertinoOwen A. O’Connor Invited Commentary Pages: 85 - 87
In vitro chemosensitivity testing and mechanisms of drug resistance Krishnansu TewariAlberto Manetta OriginalPaper Pages: 77 - 84
The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma Alberto E. SelmanLarry J. Copeland OriginalPaper Pages: 71 - 76
Vascular endothelial growth factor in ovarian cancer Darcie A. HazeltonThomas C. Hamilton OriginalPaper Pages: 59 - 63
Dose-intensive approaches to ovarian cancer Nicholas LambrouEdward L. Trimble OriginalPaper Pages: 54 - 58
Systemic therapy for advanced or recurrent endometrial carcinoma Gini F. Fleming OriginalPaper Pages: 47 - 53
Concurrent chemotherapy and radiation therapy in primary cancer of the cervix Jeanne M. SchilderFrederick B. Stehman OriginalPaper Pages: 41 - 46
New data on adjuvant therapy for breast cancer Antonio C. WolffNancy E. Davidson OriginalPaper Pages: 31 - 37
Dose-intensive chemotherapy for locally advanced breast cancer Jolanda G. SchramaSjoerd Rodenhuis OriginalPaper Pages: 23 - 30
The biology of human epidermal growth factor receptor 2 Srividya SundaresanElicia PenuelMark X. Sliwkowski OriginalPaper Pages: 16 - 22
“Clinical benefit” following treatment with antineoplastic drugs: What does it mean and how should we measure it? Maurie Markman Editor’s Commentary Pages: 1 - 2
